|
|
|
| |
World's one of the largest Research
Career Network |
|
|
|
Benefits |
- Academic & Industry jobs
- Project funding
- Visiting faculty positions
- Visiting scientist positions
- Invited talks
- and more...
|
|
|
|
|
|
|
|
Register FREE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Global Journal of Surgery 2012, 3: 2
|
|
|
Research Article
|
|
|
|
|
|
|
Kikuchi-fujimoto disease –
a series from a european centre and review of the literature
|
|
|
|
Katrin Hoffmanna, Michael A. Kernb, Gunhild Mechtersheimerb,
Moritz N Wentea, Markus W. Büchlera, Peter Schemmera
|
|
|
|
|
|
|
|
a Department of General and Transplantation Surgery, Ruprecht-Karls-University
Heidelberg, Germany
b Department of Pathology, Ruprecht-Karls-University, Heidelberg, Germany
|
|
|
|
|
|
|
|
Abstract |
|
|
|
Background: Kikuchi-Fujimoto disease is a unique histiocytic necrotizing lymphadenitis scarcely known in Europe. Due to its sudden onset and accompanying symptoms a large variety of differential diagnoses has to be considered. Case presentation: Seven cases of sudden onset cervical dominated lymphadenopathy accompanied by tenderness, fever, night sweats and weakness treated at the University Hospital of Heidelberg are reported. The patients underwent excisional lymph node biopsy for suspected malignant disease. Kikuchi-Fujimoto disease was histologically confirmed in all biopsies. Additional clinical signs such as erythematous skin lesions, Thyreoiditis de Quervain or Raynaud syndrome were documented in four patients. Symptomatic treatment was established by the administration of non-steroidal anti-inflammatory drugs. All treated cases responded and showed no recurrence. Conclusions : Kikuchi-Fujimoto disease is an important differential diagnosis in cases of sudden onset lymph node enlargement. Due to its dramatically different course and treatment a differentiation from malignant, infectious and auto-immune diseases is crucial.
|
|
|
|
|
|
|
Keywords |
|
|
|
Necrotizing lymphadenitis; Histiocytes; Lymphadenopathy
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|